Bioanalytical Assay Development and Validation for the Pharmacokinetic Study of GMC1, a Novel FKBP52 Co-chaperone Inhibitor for Castration Resistant Prostate Cancer.
Oscar EkpenyongCandace CooperJing MaNaihsuan C GuyAshley N PayanFuqiang BanArtem CherkasovMarc B CoxDong LiangHuan XiePublished in: Pharmaceuticals (Basel, Switzerland) (2020)
Pharmacokinetic evaluation of GMC1 revealed that the molecule has a biexponential disposition in rats, is distributed rapidly and extensively, has a long elimination half-life, and appears to be eliminated primarily by first order kinetics.